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a b s t r a c t
Secondary nervous system lymphoma (SCNSL) is a rare extranodal form of non-Hodgkin
lymphoma (NHL). This applies to a particular form of lymphoma that does not originally
derive from the central nervous system (CNS); it can be both an isolated form of relapse or a
systemic part of disease progression. Due to poor prognosis and a lack of established
algorithms of therapeutic procedures, it is a big challenge for physicians from many
specializations. In our study, we present an interesting case of a patient with a relapsed
form of SCNSL for whom a unique form of treatment was used – intraventricular adminis-
tration of rituximab and methotrexate.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Lymphomas of central nervous system (CNS) both in a primary
(PCNSL) and secondary form (SCNSL) are a rarely diagnosed
extranodal location of non-Hodgkin lymphomas (NHL) usually* Corresponding author at: Chair and Department of Haematooncology
Staszica 11 Str., 20-081 Lublin, Poland.
E-mail address: agnieszka.szymczyk.med@wp.pl (A. Szymczyk).
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0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Swith poor prognosis. SCNSL is a particular type of lymphoma,
which does not initially derive from the CNS; it can present
both as an isolated form of relapse or a systemic part of disease
progression [1]. SCNSL is usually detected within a few weeks
or months after a diagnosis of systemic lymphoma. It affects
both the brain and cerebral meninges [2]. PCNSL is treated with
chemotherapy based on high doses of methotrexate (MTX) [3]. and Bone Marrow Transplantation, Medical University of Lublin,
p. z o.o. All rights reserved.
Fig. 1 – T1-weighted contrast-enhanced MR imaging
presents contrast enhancement of the tissue infiltrating
the right lateral ventricle wall before treatment.
Fig. 2 – T1-weighted contrast-enhanced MR imaging
presents radical regression of infiltrating changes in the
right lateral ventricle wall after treatment.
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CNS lymphomas, is a particularly difﬁcult challenge and
creates many more doubts. In this study, we present a case of a
patient with a relapsed form of a secondary CNS lymphoma for
whom a unique form of treatment was used – intraventricular
administration of rituximab and methotrexate.
2. Case presentation
In March 2013, diffuse large B-cell lymphoma (DLBCL, NOS;
CD20+, CD5+/, CD10+, BCL2+, BCL6+, MUM1/CD43-, Ki-67++
approx. 50% of cells) at stage IV B was diagnosed in a 74-year-
old man on the basis of a histological examination of a
pancreas sample and the surrounding lymph nodes. A total of
8 cycles of R-CHOP immunochemotherapy was ordered. In
result complete remission (CR) was obtained. At the same
time, the patient was receiving a hormone therapy due to
prostate cancer. In September 2015 (with CR lasting 21 months)
an isolated recurrence of lymphoma in the CNS, affecting the
meninges and ependyma, was discovered and radiotherapy
was started. A dose of 3000 cGy radiation was used on the brain
and the medulla oblongata. A check-up PET examination
revealed complete regression of lymphomatous lesions in the
CNS and no relapse of the tumour of lymphoma in other parts
of the body. After a 4-month observation, the patient's general
condition deteriorated, and progressive psychomotor slow-
down and memory disorders were observed. After another two
months, a generalised epileptic seizure occurred. In April 2016
an MRI scan of the head showed a lymphomatous inﬁltration
of the brain, the lateral ventricular walls, the septum
pellucidum and the 3rd ventricle (Fig. 1 presents contrast
enhancement of the tissue inﬁltrating the right lateral
ventricle wall). An examination of the cerebrospinal ﬂuid
(CSF) did not reveal the presence of lymphomatous cells. The
test for human immunodeﬁciency virus (HIV) was negative,
however the test for the Epstein–Barr virus (EBV) was not
performed.
The patient was qualiﬁed for the Ommaya reservoir
implantation to administer chemotherapy. Such a
decision was made due to the patient's advanced age, general
condition (ECOG-3) and numerous co-existing diseases (pros-
tate cancer, distal pancreatic resection in case history,
degenerative spine disease, hypothyroidism, hypertension,
diabetes). At the same time the patient did not consent to
systemic chemotherapy. The treatment regimen consisted of
simultaneous administration of rituximab (25 mg) and meth-
otrexate (10 mg) twice a week for 4 weeks (8 doses in total).
During the entire uneventful course of the intraventricular
immuno-chemotherapy, steroid medications were not used,
however considerable improvement in the psychomotor
condition of the patient occurred. After therapy completion,
an MRI check-up revealed considerable regression of changes
in the CNS (Fig. 2). On treatment cycle end the patient was
transferred to the Long-Term Care Unit. Unfortunately, he did
not consent to further treatment. The documented period of
the stable neurological state conﬁrmed with CT was 7 months.
Information about the later patient's medical history is not
known.
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Diffuse large B-cell lymphomas (DLBCL) are one of the most
often diagnosed types of non-Hodgkin lymphomas [4]. The
use of regimens containing rituximab, vincristine, cyclophos-
phamide and prednison (R-CHOP) has made it possible to cure
50–60% of patients [5]. However, therapy of subjects with
recurrent disease, especially affecting the central nervous
system, is still a big problem. It is a particularly unfavourable
location in terms of prognosis. The overall median survival
time is 3–6 months [6]. The incidence of the isolated CNS
recurrence in course of DLBCL is diagnosed in 1.1–10.4% of
cases. Such a considerable discrepancy between the data
probably results from the high diversity of presented groups
and a lack of uniform methods assessing changes in the CNS
[2,7–13]. The most frequently recommended and, at the same
time, most modern and most sensitive diagnostic methods
include magnetic resonance imaging and ﬂuorescence-acti-
vated cell sorting analysis of CSF. Their use makes it possible to
detect CNS lymphomatous inﬁltration in cases where it would
not be possible with the use of traditional methods [14,15].
It was reported that an introduction of rituximab into
treatment regimens had a signiﬁcant, advantageous effect on
reducing the number of the recurrences of the diseases in the
CNS [9,16]. This is, however, not conﬁrmed by other research-
ers [6,17]. Rituximab is a monoclonal antibody characterised by
poor penetration of the blood–brain barrier. After intravenous
administration, its concentration in the cerebrospinal ﬂuid
reaches only 0.1% of that in the serum [18]. However, it was
also shown that it could be effective during the ﬁrst week of
therapy when the blood–brain is probably destroyed by
actively growing tumour tissues [19]. The problem of poor
permeation to the CNS also applies to other drugs included
into the CHOP regimen. This may account for the occurrence of
isolated recurrences of lymphoma in the CNS with a
simultaneous lack of symptoms of the systemic disease [20].
The prognosis for patients with both PCNSL and the
secondary form of the CNS disease improved signiﬁcantly
when, at the end of the 1970s, Ervin et al. proved the
effectiveness of intravenous treatment with large doses of
methotrexate [21]. It was also established that primary diffuse
large B-cell lymphomas situated in the CNS are over three
times more sensitive to Mtx as compared to systemic
lymphomas (the mechanism of this phenomenon is unknown
as yet) [22].
In the presented case report an inﬁltration in the CNS was
detected ﬁrst time at 21 month after lymphoma diagnosis. The
median time of CNS recurrence in an analogical group of
patients is about 7.2 months. Such a short time of relapse may
be connected with a subclinical presence of abnormalities in
the CNS at the moment when DLBCL is diagnosed and a lack of
sufﬁcient penetration of the CNS by drugs of standard
therapeutic regiments [23].
The treatment of lymphoma recurrence in the CNS is a
particularly difﬁcult challenge. There are no uniform diagnos-
tic and therapeutic algorithms, thus the individual decisions
considering numerous factors, such as the patient's age and
clinical status, previous treatment and co-existing diseases,
should be made. Research analysis in this ﬁeld, which is oftenretrospective and includes variable groups of patients, does
not provide any useful suggestion. So regimens used in
primary cerebral lymphomas therapy are quite often used in
the treatment of secondary CNS lymphomas as well. However,
their effectiveness is considerably lower [24]. CNS lymphomas
are highly sensitive to whole brain radiation therapy (WBRT),
that, however, has a lot of harmful side-effects. The median
overall survival time of patients, for whom it was the only one
type of treatment, was about 11 months, and the disease
recurred in over a half of the patients in the irradiated area.
The most frequent complications include: urinary inconti-
nence as well as walking and memory disorders. They occur
mostly in patients who are over 60 years old, usually a year
after the end of radiotherapy, and they signiﬁcantly reduce the
quality of their life [25].
Korefel et al., in the phase II prospective study, pointed to
the possibility of the application of systemic, high-dose
chemotherapy, combined with autologous stem-cell trans-
plantation (ASCT) in SCNSL in group of patients below 65 years
of age. This could give the chance of an approximate 2-year
disease control period in approx. 50% of patients [26].
A combination of rituximab and high-dose sequential
chemotherapy and ASCT constitutes an interesting treatment
option. Ferreri et al. demonstrated the high effectiveness of
this type of treatment in the group of patients between 18 and
70 years of age. Particular attention should be paid to the fact
that 2/3 of patients who underwent ASCT and remained in CR
for a 5-year observation period [27]. High-dose chemotherapy
with ASCT is used to intensify the treatment and to break the
resistance to treatment [28].
The recent comprehensive genomic analyses served as a
basis for attempts to apply nivolumab (human programmed
death receptor-1 blocking antibody) in patients with a
resistant/recurrent form of PCNSL [29]. Experimental treat-
ment with ibrutinib [30], lenalidomid combined with ritux-
imab [31], and anti-CD19 CAR T cells, is a very promising
option, too [32].
Intraventricular or intrathecal administration of cytostatics
combined with systemic chemotherapy was included in
treatment regimens. Stereotactic placement of Ommaya
reservoir, provides such an opportunity [33]. One of the
best-known systems using this method is the Bonn multi-
drug regimen, assessed by Pels et al. in the ﬁrst line therapy in
65 PCNSL patients. The authors obtained a high percentage of
responses – 71% (61% CR and 10% PR). The median overall
survival in the group over 60 years of age was 34 months; it was
not achieved in the group of younger patients [34].
In the ﬁrst prospective phase I study, Rubinstein et al.
analysed the effectiveness and safety of intraventricular
immunochemotherapy (rituximab + methotrexate) in patients
with a recurrent or resistant form of PCNSL. This study was
established as a response to the need for looking for the new
methods of treatment of this highly selected group of patients
with an extremely poor prognosis. In 75%, total eradication of
lymphoma cells from the CSF was achieved and in 43% of
patients that was also applied to the brain. Regression of
lymphomatous lesions was found in the corpus callosum and
in the basal ganglia, structures that are thought to be difﬁcult
to reach as for cytostatic drugs solved in the cerebral spinal
ﬂuid. Pharmacokinetic tests performed in this study revealed
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with Mtx. The administration of both drugs slowed down the
elimination of the monoclonal antibody probably caused by a
change of the CSF ﬂow. This promotes maintaining constant
concentrations of this protein, which is of great importance in
the prevention of rituximab resistance [24].
The intraventricular dose of rituximab (25 mg) resulted
from previous experiments by Rubinstein et al. The authors
assessed the effectiveness of rituximab monotherapy with
intraventricular administration through the Ommaya reser-
voir in a group of 10 patients with recurrent, primary or
secondary cerebral lymphomas. The drug was initially used
once a week (during the ﬁrst week) and next twice a week (for
the next four weeks). From the administered doses (10, 25 and
50 mg), after the subsequent re-assessment of the patient's
condition, 10 and 25 mg proved to be the most effective and
safest doses [18]. A subsequent study by Rubinstein included
14 patients after a few lines of treatment (including 11 with
DLBCL) with a recurrent/resistant form of CNS lymphoma. A
secondary form of CNS lymphoma was found in eight of them,
and WBRT had been provided previously to 2 of them [24].
In the presented case the decision on the use of
intraventricular injections of rituximab and methotrexate
resulted from an advanced age of patient, numerous co-
existing diseases (including cancer), poor general condition
and patient's decision. No symptoms of intolerance were
observed during the therapy and a surprising considerable
improvement in the patient's neurological state was achieved,
which was conﬁrmed by MRI scans. In our opinion, the efﬁcacy
of intraventricular chemotherapy results from the direct
effects that drugs in CSF have had on the lesions inﬁltrating
the lateral ventricle lining. Grossman and co-authors' research
assessing the efﬁcacy of intraventricular methotrexate ad-
ministration suggest that high drug concentration may only be
expected in the immediate vicinity of the chambers, while the
other areas of the brain may reach the drug at much lower
concentrations [35].
It is possible, however, that even a small dose of the drug
might be effective, at least in some cases, especially when the
injections are repeated.
In patients with recurrent/refractory CNS lymphoma who
did not qualify for intensive chemotherapy, attempts were
made to use temsirolimus monotherapy. Unfortunately,
despite demonstrating the activity of the drug in the study
group, the effect was short-lived (median progression-free
survival was 2.1 months) [36]. A retrospective analysis of Wang
et al. regarding PCNSL patients presented a beneﬁcial effect of
using high-dose methotrexate plus temozolamide. The
authors also suggest the possibility of undertaking an
analogous therapy in patients with more advanced age and
poor general condition. However, all these proposals require
further research [37].
4. Summary
Intraventricular immunochemotherapy is a safe and effective
therapeutic option, sometimes the only available one, for
patients with an isolated recurrence of CNS lymphoma. It is
mostly targeted at patients in poor general condition whocannot receive intensive chemotherapy. Due to the fact that so
far it has been used in single cases only, a lot of questions still
need to be answered. This applies the possibility of a potential
increase in the rituximab and methotrexate doses or the
possibility of increasing a number of treatment cycles used.
The promising results, which have been presented in our
study, should encourage further research on this issue.
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